***NEW PODCAST - ANNEXA-I*** Pleased to release the latest episode of "Don't Just Read the Abstract" podcast with @PipNicolson. In this episode, we discuss ANNEXA-I - andexanet alfa vs usual care for intracerebral haemorrhage. It's a lively discussion! On all podcast platforms.

Now THAT is a prescribing cascade @CarolynTanMD

The NHS Fellowship in Clinical AI is inviting haematology project proposals for its 12-month, part-time programme (0.4 FTE, Aug 2026 start). 🔗 Info & FAQ: https://t.co/vQNSvlgXeI 📅 Deadline: 8 Dec 2025 📧 gstt.aifellowship@nhs.net

https://t.co/zwu27wf7zw Really pleased to be able to share results of our worldwide survey on management of secondary polycythaemia. Highly variable practice regarding who is venesected, Hct thresholds and targets @Eman__Hassan__ @richardbuka @lymphomule @doyley1_

My goodness, a lot of sense in this article. 1) Simplify the tax system, 2) get rid of the 100k cliff edge (I know people working as little as possible to avoid) and 3) make childcare wholly tax deductible. @MoneyWeek https://t.co/gjjYzUXq2H

Really fantastic to be able to share this interview that has been a long time coming! @PipNicolson and I had a wonderful opportunity to catch up with @BritSocHaem President Dr Sue Pavord on everything she has been doing with BSH + some extra nuggets including #VITT

Great to see this in Blood this edition. Saw it presented at @ASH_hematology 2024 and was very impressed. Impaired secretion of Weibel-Palade bodies as a cause of vWD. Hope to see this added to our genetics panels. Shows how much we have to learn!

This is the latest edition of the Don't Just Read the Abstract Newsletter. To sign-up for updates in medical haematology, go to dontjustreadtheabstract . com This wk, we focus on some work that @BritSocHaem have done on defining liaison haematology. @PipNicolson @eleanor__p

Here's a thought. Is apixaban safer than rivaroxaban because people forget to take it twice a day so in general get a cumulatively lower dose?

2 trials reinforce less is more with anti-platelet & DOACs: 1. AQUATIC (NEJM): Adding ASA to DOACs in chronic coronary syndrome = ↑ death + bleeding 2. ATIS‑NVAF (JAMA): Adding ASA to DOACs after stroke w/ concurrent Afib+ASCVD = no benefit + ⬆️ 🩸 #HemeTwitter #MedTwitter

A simple but often misunderstood concept How specific cytogenetic and genomic abnormalities affect the risk of progression from premalignancy to malignancy may be quite different from how they affect risk of progression and survival after diagnosis of malignancy. A given

#WorldThrombosisDay draws attention to the hidden global burden of thrombosis. In support of #WTDay25, join the NATA webinar 16 Oct #Anticoagulant & #Antifibrinolytic Stewardship — for HCPs eager to master evidence-based thrombosis management. 🔗 https://t.co/eIXzBqpVX5

The brand new, Don't Just Read the Abstract newsletter. A twice monthly email about goings on in medical haematology. Subscribe at dontjustreadtheabstract. com

Sorry but I fail to see how what price the NHS pays for drugs (prices that the companies agreed to), leads to reduced investment in UK by pharma. Total BS. The two are not linked. R&D is a global business, UK sales is small fry.

Exciting times I think. There is unmet need here. We need proof that giving reversal agents actually improves clinical outcomes. I will be advocating hard for this - another surrogate outcome trial is not going to cut it.

So, this could be a very smart move for both companies - CSL are getting skin in the game for a molecule with promising data - for an initial $117 million with further milestone payments ($388 mil). VarmX are getting funding for their trials.

This molecule is given to the patient as a single IV injection, giving them a factor Xa that is resistant to inhibition. In non-human primates, VMX-C001 reduces bleeding time & amount post liver injury. A phase I human trial reported no adverse events and consistent PK data.

To make this molecule, they took an amino acid sequence from the factor X like-molecule found in the venom of the Australian Brown Snake. They then engineered this into human factor Xa (the red bit on the image) which blocks drug binding to the active site.

VarmX's molecule is a neat piece of bioengineering. The brain child of Prof Pieter Rietsma (discoverer of factor V Leiden), VMX-C001 is a bypassing agent - a Factor X molecule that has been modified to be resistant to inhibition by apixaban and rivaroxaban.

There is only one licensed reversal agent for apixaban and rivaroxaban - andexanet alfa. Despite the flaws with this drug and the lack of evidence of true clinical benefit, it'll probably make at least $1.5-2.5 bn before patent expiry unless something disrupts the market.

Bit of pharma news here. CSL Behring have announced a colab with Dutch biotech, VarmX. VarmX have been working on a very exciting molecule that is an antidote oral FXa inhibitors like rivaroxaban and apixaban. What is this molecule? And why is it worth a potential $1.7bn? A🧵